THE NATURAL HISTORY OF TYPE 2 DIABETES

Antonucci, 1997, Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone, Diabetes Care, 20, 188, 10.2337/diacare.20.2.188

Bonora, 1998, Prevalence of insulin resistance in metabolic disorders: The Bruneck study, Diabetes, 47, 1643, 10.2337/diabetes.47.10.1643

1996, Consensus Statement: The pharmacologic treatment of hyperglycemia in NIDDM, Diabetes Care, 19, 354S

DeFronzo, 1995, Efficacy of metformin in patients with non–insulin-dependent diabetes mellitus, N Engl J Med, 333, 541, 10.1056/NEJM199508313330902

Diabetes Prevention Program Research Group, 1998

Draznin, 1998, Troglitazone plus sulfonylurea combination: Long-term efficacy in patients with type 2 diabetes. [abstract 0330], Journal of the American Diabetes Association, 47, A85

Edelman, 1995, Impaired glucose tolerance: A precursor of NIDDM or a disease entity in itself?, Diabetes, 16, 1

Edelstein, 1997, Predictors of progression from impaired glucose tolerance to NIDDM: An analysis of six prospective studies, Diabetes, 46, 701, 10.2337/diabetes.46.4.701

Eriksson, 1989, Early metabolic defects in persons at increased risk for non–insulin-dependent diabetes mellitus, N Engl J Med, 321, 337, 10.1056/NEJM198908103210601

Eriksson, 1996, Poor physical fitness, and impaired early insulin response but late hyperinsulinemia as predictors of NIDDM in middle-aged Swedish men, Diabetologia, 39, 573, 10.1007/BF00403304

Eriksson, 1991, Prevention of type 2 (non–insulin-dependent) diabetes mellitus by diet and physical exercise: The 6-year Malmo Feasibility Study, Diabetologia, 34, 891, 10.1007/BF00400196

Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, 1997, Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care, 20, 1183, 10.2337/diacare.20.7.1183

Fagan, 1998, The cardiovascular dysmetabolic syndrome, Am J Med, 105, 77, 10.1016/S0002-9343(98)00216-2

Haffner, 1990, Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?, JAMA, 263, 2893, 10.1001/jama.1990.03440210043030

Harris, 1997, Consultant, 37, S9

Harris, 1989, Impaired glucose tolerance in the US population, Diabetes Care, 12, 464, 10.2337/diacare.12.7.464

Harris, 1987, Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20–74 years, Diabetes, 36, 523, 10.2337/diabetes.36.4.523

Harrower, 1994, Comparison of efficacy, secondary failure rate, and complications of sulfonylureas, J Diabetes Complications, 8, 201, 10.1016/1056-8727(94)90044-2

Henry, 1998, Type 2 diabetes care: The role of insulin-sensitizing agents and practical implications for cardiovascular disease prevention, Am J Med, 105, 20, 10.1016/S0002-9343(98)00207-1

Horton, 1998, Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes, Diabetes Care, 21, 1462, 10.2337/diacare.21.9.1462

Hsueh, 1998, Cardiovascular risk continuum: Implication of insulin resistance and diabetes, Am J Med, 105, 4, 10.1016/S0002-9343(98)00205-8

Leahy, 1990, Natural history of beta-cell dysfunction in NIDDM, Diabetes Care, 13, 992, 10.2337/diacare.13.9.992

Long, 1994, Weight loss in severely obese subjects prevents the progression of impaired glucose tolerance to type II diabetes, Diabetes Care, 17, 372, 10.2337/diacare.17.5.372

Matsuzawa, 1997, Pathophysiology and molecular mechanisms of visceral fat syndrome, Diabetes Metab Rev, 13, 3, 10.1002/(SICI)1099-0895(199703)13:1<3::AID-DMR178>3.0.CO;2-N

Matthews, 1998, UKPDS 26: Sulphonylurea failure in non–insulin-dependent diabetic patients over six years, Diabet Med, 15, 297, 10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.3.CO;2-N

McPhillips, 1990, Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non–insulin-dependent diabetes mellitus in a community of older adults, Am J Epidemiology, 131, 443, 10.1093/oxfordjournals.aje.a115519

National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995, Diabetes Statistics, 1

Nolan, 1994, Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone, N Engl J Med, 331, 1188, 10.1056/NEJM199411033311803

Perry, 1995, Prospective study of risk factors for development of non–insulin-dependent diabetes in middle aged British men, BMJ, 310, 560, 10.1136/bmj.310.6979.560

Rewers, 1995, Risk factors for non–insulin-dependent diabetes

Ruderman, 1998, The metabolically obese, normal-weight individual revisited Diabetes, 47, 699

UK Prospective Diabetes Study Group, 1998, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet, 352, 837, 10.1016/S0140-6736(98)07019-6

Warram, 1990, Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents, Ann Intern Med, 113, 909, 10.7326/0003-4819-113-12-909